
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. has demonstrated strong financial growth, with Cell Processing revenue reaching $25.3 million, up 33% year-over-year, and evo and Thaw revenue increasing to $2.8 million, up 15% year-over-year. The company has also raised its 2025 revenue guidance to between $100 to $103 million, reflecting a projected 22-25% growth, supported by robust expectations for Cell Processing and evo and Thaw revenue. Additionally, management anticipates a reduction in net loss and continued improvement in adjusted EBITDA margins, indicating a positive trajectory for the company's financial health.
Bears say
BioLife Solutions Inc faces several fundamental risks that contribute to a negative outlook, including lower-than-projected growth of products and services, difficulty in securing additional customers, and fluctuations in sales due to foreign exchange rates. The company reported a significant net loss of $15.8 million, primarily influenced by a $15.5 million in-process research and development expense associated with the PanTHERA transaction, which exceeded previous estimates. Furthermore, revenue guidance for FY2025 was adjusted downwards, reflecting a decrease of approximately $8 million and projecting only 27-29% year-over-year growth, raising concerns about the sustainability of its Cell Processing revenue stream.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares